Table 2.
Pretreatment drug resistance mutations detected and their resistance pattern to common drugs
| Sample ID | Age/Sex | Viral load (copies/ml) | Mutations type | |||||
|---|---|---|---|---|---|---|---|---|
| NNRTIs | Resistant to | NRTIs | Resistant to | PIs | Resistant to | |||
| MT416676 | 32/F | 134,263 | None | None | G73S* | ATV/ra | ||
| MT416698 | 37/F | 124,246 | K103N | EFVc, NVPc | None | None | ||
| MT416672 | 45/M | 19,652 | Y188L, H221Y, L234I* | ETRa, DORc, EFVc, NVPc, RPVc | Y115F, M184V | ABCc, FTCc, 3TCc | None | |
| MT416680 | 40/M | 443,919 | K101E | ETRa, EFVa,NVPb, RPVb, DORa | None | None | ||
| MT416667 | 25/F | 66,791 | V106A, E138A | ETRa, DORc, EFVb, NVPc, RPVa | None | None | ||
| MT416710 | 27/F | 14,498 | E138A | ETRa, RPVa | None | None | ||
F Female, M Male, ATV/r Atazanavir/ritonavir, ABC Abacavir, FTC Emtricitabine, 3TC Lamivudine, DOR Doravirine, EFV Efavirenz, ETR Etravirine, NVP Nevirapine, RPV Rilpivirine, NRTI nucleoside reverse transcriptase inhibitor; NNRTI non-NRTI, PI protease inhibitor
aLow-level resistance, bIntermediate-level drug resistance, cHigh-level drug resistance
Mutations in bold, are PDRMs by both IAS-USA and the CPR tool; Mutation in Italics are reported by IAS-USA only. While indicated by * only detected by the CPR tool